These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

233 related articles for article (PubMed ID: 38520029)

  • 1. What should rheumatologists know about Gaucher disease and Fabry disease? Connecting the dots for an overview.
    Cordeiro RA; Rosa Neto NS; Giardini HAM
    Adv Rheumatol; 2024 Mar; 64(1):22. PubMed ID: 38520029
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rheumatologic aspects of lysosomal storage diseases.
    Manger B; Mengel E; Schaefer RM
    Clin Rheumatol; 2007 Mar; 26(3):335-41. PubMed ID: 16680390
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Lysosomal storage diseases].
    Manger B
    Z Rheumatol; 2010 Aug; 69(6):527-38. PubMed ID: 20532791
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cardiac involvement in Lysosomal Storage Diseases.
    Sestito S; Parisi F; Tallarico V; Tarsitano F; Roppa K; Pensabene L; Chimenz R; Ceravolo G; Calabrò MP; De Sarro R; Moricca MT; Bonapace G; Concolino D
    J Biol Regul Homeost Agents; 2020; 34(4 Suppl. 2):107-119. SPECIAL ISSUE: FOCUS ON PEDIATRIC CARDIOLOGY. PubMed ID: 33000609
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Gaucher disease, Fabry disease and mucopolysaccharidosis type I--how can the rheumatologist recognise these patients?].
    Manger B; Menge E; Schaefer R; Haase C; Seidel J; Michels H
    Z Rheumatol; 2006 Feb; 65(1):32, 34-43. PubMed ID: 16467949
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The patient journey of patients with Fabry disease, Gaucher disease and Mucopolysaccharidosis type II: A German-wide telephone survey.
    Mengel E; Gaedeke J; Gothe H; Krupka S; Lachmann A; Reinke J; Ohlmeier C
    PLoS One; 2020; 15(12):e0244279. PubMed ID: 33382737
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Gaucher disease and Fabry disease: new markers and insights in pathophysiology for two distinct glycosphingolipidoses.
    Ferraz MJ; Kallemeijn WW; Mirzaian M; Herrera Moro D; Marques A; Wisse P; Boot RG; Willems LI; Overkleeft HS; Aerts JM
    Biochim Biophys Acta; 2014 May; 1841(5):811-25. PubMed ID: 24239767
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Detecting multiple lysosomal storage diseases by tandem mass spectrometry--a national newborn screening program in Taiwan.
    Liao HC; Chiang CC; Niu DM; Wang CH; Kao SM; Tsai FJ; Huang YH; Liu HC; Huang CK; Gao HJ; Yang CF; Chan MJ; Lin WD; Chen YJ
    Clin Chim Acta; 2014 Apr; 431():80-6. PubMed ID: 24513544
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [How does the landscape change in lysosomal storage disease].
    Parini R
    Pediatr Med Chir; 2007; 29(5):275-8. PubMed ID: 18402399
    [No Abstract]   [Full Text] [Related]  

  • 10. Patients' view on gene therapy development for lysosomal storage disorders: a qualitative study.
    Eskes ECB; Beishuizen CRL; Corazolla EM; van Middelaar T; Brands MMMG; Dekker H; van de Mheen E; Langeveld M; Hollak CEM; Sjouke B
    Orphanet J Rare Dis; 2022 Oct; 17(1):383. PubMed ID: 36271424
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lysosomal storage diseases as differential diagnoses to rheumatic disorders.
    Michels H; Mengel E
    Curr Opin Rheumatol; 2008 Jan; 20(1):76-81. PubMed ID: 18281861
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Importance of lysosomal storage diseases in rheumatology].
    Aries C; Rudolph C; Muschol N
    Z Rheumatol; 2024 Jun; 83(5):393-400. PubMed ID: 38802503
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatable lysosomal storage diseases in the advent of disease-specific therapy.
    Peters H; Ellaway C; Nicholls K; Reardon K; Szer J
    Intern Med J; 2020 Nov; 50 Suppl 4():5-27. PubMed ID: 33210402
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of pentosan polysulfate in in vitro models of lysosomal storage disorders: Fabry and Gaucher Disease.
    Crivaro AN; Mucci JM; Bondar CM; Ormazabal ME; Ceci R; Simonaro C; Rozenfeld PA
    PLoS One; 2019; 14(5):e0217780. PubMed ID: 31150494
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lysosomal storage disorder screening implementation: findings from the first six months of full population pilot testing in Missouri.
    Hopkins PV; Campbell C; Klug T; Rogers S; Raburn-Miller J; Kiesling J
    J Pediatr; 2015 Jan; 166(1):172-7. PubMed ID: 25444528
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Newborn Screening for Lysosomal Storage Disorders.
    Anderson S
    J Pediatr Health Care; 2018; 32(3):285-294. PubMed ID: 29678259
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Enzymatic abnormalities in diseases of sphingolipid metabolism.
    Brady RO
    Clin Chem; 1967 Jul; 13(7):565-77. PubMed ID: 5006481
    [No Abstract]   [Full Text] [Related]  

  • 18. Rapid screening for lipid storage disorders using biochemical markers. Expert center data and review of the literature.
    Voorink-Moret M; Goorden SMI; van Kuilenburg ABP; Wijburg FA; Ghauharali-van der Vlugt JMM; Beers-Stet FS; Zoetekouw A; Kulik W; Hollak CEM; Vaz FM
    Mol Genet Metab; 2018 Feb; 123(2):76-84. PubMed ID: 29290526
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Biomarkers in the diagnosis of lysosomal storage disorders: proteins, lipids, and inhibodies.
    Aerts JM; Kallemeijn WW; Wegdam W; Joao Ferraz M; van Breemen MJ; Dekker N; Kramer G; Poorthuis BJ; Groener JE; Cox-Brinkman J; Rombach SM; Hollak CE; Linthorst GE; Witte MD; Gold H; van der Marel GA; Overkleeft HS; Boot RG
    J Inherit Metab Dis; 2011 Jun; 34(3):605-19. PubMed ID: 21445610
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Levels of Lyso GL-1 in Gaucher and Lyso GL-3 in Fabry patients from India: Diagnostic aids for these lysosomal storage disorders.
    Verma J; Roy P; Thomas DC; Dua Puri R; Verma IC
    Clin Chim Acta; 2021 Oct; 521():177-190. PubMed ID: 34280392
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.